Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …

PURPOSE Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …

Discovery of imatinib mesylate (IM) as the targeted BCR-ABL protein tyrosine kinase
inhibitor (TKI) has resulted in its use as the frontline therapy for chronic myeloid leukemia …

Mutations of the BCR-ABL1 kinase domain seem to be the most common cause of imatinib
mesylate resistance in chronic myeloid leukemia (CML). We screened BCR-ABL1 kinase …

Abstract Mutations in the Bcr-Abl kinase domain (KD) are a major cause for acquired
resistance to imatinib (IM) treatment and have been associated with progression and poor …

We document the characteristics of BCR-ABL kinase domain mutations (KDM) in the largest
study from India comprising of 385 patients and demonstrate that more than half (51.9%) of …

BCR-ABL kinase domain (KD) mutation is the main mechanism associated with resistance
to tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) patients. This study …

The aim of the present study was to analyse the incidence of mutations in the BCR‑ABL1
kinase region in patients with newly diagnosed or treated chronic myeloid leukaemia (CML) …

Background: Additional chromosome abnormalities (ACAs), mutations of the BCR-ABL
tyrosine kinase domain (TKD) and BCR-ABL splice variants may cause resistance to first …

Mutations of the BCR-ABL tyrosine kinase domain constitute a major cause of resistance to
tyrosine kinase inhibitors in patients with chronic myelogenous leukemia (CML). In this …